Cyclo3pss Corporation (CYPS) Stock Analysis

Cyclo3pss Corporation (CYPS) Healthcare & Pipeline Overview

Cyclo3pss Corporation, founded in 1927, historically specialized in ozone food processing products, commercial laundry systems, and R&D for sterilization technologies. Based in Salt Lake City, Utah, the company suspended all operations in July 2002 due to an inability to secure necessary financing, marking its current dormant status within the Healthcare sector.

What Is the Investment Thesis for CYPS?

The investment thesis for Cyclo3pss Corporation (CYPS) is fundamentally shaped by its current operational status. The company, which historically engaged in ozone food processing products, commercial laundry systems, and sterilization R&D, formally suspended all operations in July 2002. This suspension was a direct consequence of an inability to secure necessary financing and attract willing investors. As of the current date, there is no indication from the provided data that operations have resumed or are planned to resume. Financially, CYPS exhibits a market capitalization of $0.00 billion and a free cash flow of $-0.00 billion, reflecting its dormant state. The reported profit margin of -232.3% and a gross margin of 36.6% are historical metrics that predate or immediately followed the operational suspension, highlighting significant financial challenges. With a beta of 21.99, the stock historically demonstrated extreme volatility, though this metric's relevance is diminished given the lack of active trading and operations. Value drivers are currently non-existent, as the company generates no revenue and has no active business. Any potential for future value would hinge entirely on an unforeseen and unannounced revival of operations, which is not supported by current information.

Based on FMP financials and quantitative analysis

CYPS Key Highlights

Market Capitalization: Reported at $0.00 billion, reflecting the company's dormant status and minimal market valuation.

• Profit Margin: A historical profit margin of -232.3% indicates significant unprofitability during its operational period or immediately prior to suspension.
• Gross Margin: A gross margin of 36.6% suggests that while the company could generate revenue above direct costs, operational expenses significantly outweighed this.
• Free Cash Flow: Recorded at $-0.00 billion, consistent with a company that has suspended all operations and is not generating cash.
• Operational Status: All company operations were suspended in July 2002 due to an inability to secure necessary financing, rendering it currently inactive.

Who Are CYPS's Competitors?

CYPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CYPS's Key Strengths?

Historical expertise in ozone-based sterilization and processing technologies.

• Established R&D capabilities in consumer product disinfection.
• Long operating history since 1927, indicating foundational knowledge.
• Specialized product offerings for niche industrial applications.

What Are CYPS's Weaknesses?

Suspended all operations in July 2002 due to financial insolvency.

• Inability to secure necessary and suitable financing.
• Extremely negative profit margin (-232.3%) historically.
• Minimal employee base (4 employees) indicating limited operational capacity.

What Could Drive CYPS Stock Higher?

CYPS catalyst: The company suspended all operations in July 2002 due to an inability to secure necessary financing, indicating no active business catalysts.

• No upcoming operational catalysts are identified as the company remains dormant. Any future catalysts would depend on a successful capital raise and a decision to resume business activities, which is not indicated by the provided data.

What Are the Key Risks for CYPS?

All company operations have been suspended since July 2002, leading to no active revenue generation or business activities.

• Persistent inability to secure necessary and suitable financing, which was the stated reason for operational suspension.
• Extreme historical unprofitability, evidenced by a profit margin of -232.3%, suggesting significant challenges if operations were to resume.
• Very high historical beta of 21.99, indicating extreme price volatility and speculative nature if the stock were actively traded.
• Lack of public disclosure and transparency ("Unknown" disclosure status) poses significant information risk for investors.

What Are the Growth Opportunities for CYPS?

• Reactivation of Ozone Food Processing Division: If Cyclo3pss Corporation were to reactivate its operations, a potential growth opportunity would lie in re-entering the ozone food processing market. This market, driven by increasing consumer demand for natural preservation methods and stringent food safety regulations, could offer a pathway for renewed revenue. The global food processing equipment market was valued at over $100 billion in recent years, with sterilization and preservation technologies forming a significant component. Re-establishing its licensing, manufacturing, and sales channels for these products, potentially with updated technology, would require substantial capital investment and strategic partnerships. However, based on the provided data, the company suspended all operations in July 2002 and has not indicated any plans for reactivation, rendering this a purely hypothetical opportunity.
• Modernization of Commercial Laundry Systems: Another hypothetical growth avenue, should the company resume operations, would involve modernizing and re-introducing its ozone washing and laundry sorting and counting systems. The commercial and institutional laundry market continues to evolve, with a growing emphasis on energy efficiency, water conservation, and advanced automation. A revitalized Cyclo3pss could develop next-generation ozone systems that offer superior performance, reduced environmental impact, and enhanced data analytics for operational efficiency. This would target a market that seeks innovative solutions to lower operating costs and improve hygiene standards. However, as the company suspended all operations in July 2002 due to an inability to secure financing, this opportunity is not currently applicable.
• Expansion of Sterilization R&D into New Applications: Historically, Cyclo3pss engaged in research and development for the sterilization and disinfection of certain consumer products. If operations were to resume, a significant growth opportunity could involve leveraging this R&D expertise to develop new applications for ozone technology beyond its traditional food and laundry sectors. This could include medical device sterilization, air and water purification systems, or even household disinfection products, tapping into broader public health and environmental markets. However, given the company's operational suspension since July 2002 due to financial constraints, there are no ongoing R&D activities or identified pathways for such expansion.
• Strategic Partnerships for Technology Licensing: In a hypothetical scenario where Cyclo3pss reactivates, its historical intellectual property in ozone technology could be a valuable asset for strategic partnerships. Licensing its proprietary ozone food processing or laundry system technologies to larger, established manufacturers or distributors could provide a low-capital entry point back into the market. Such partnerships could accelerate market penetration and generate royalty income without requiring extensive direct operational investment. This strategy would capitalize on its historical R&D and product development. However, as the company suspended all operations in July 2002 due to an inability to locate willing investors and secure financing, this remains a theoretical opportunity without current applicability.
• Targeting Emerging Markets for Sanitation Solutions: If Cyclo3pss were to resume operations, a potential growth opportunity could involve targeting emerging markets that are increasingly investing in modern sanitation infrastructure and food safety standards. These markets often present less saturated competitive landscapes and a high demand for cost-effective, efficient disinfection and processing technologies. Adapting its ozone systems to meet the specific needs and regulatory environments of these regions could open new revenue streams. However, the company's operations have been suspended since July 2002 due to a lack of financing, and there is no indication of active business development or market expansion initiatives. Therefore, this opportunity is purely speculative in the current context.

What Threats Does CYPS Face?

• Continued operational dormancy leading to irrelevance and potential delisting.
• Technological obsolescence of historical products and R&D if not updated.
• Intense competition from active companies in the sterilization and industrial sanitation markets.
• Inability to attract capital for any potential future restart of operations.

What Are CYPS's Competitive Advantages?

• Historical specialization in ozone-based technologies for specific industrial applications.
• Proprietary knowledge and intellectual property developed through its R&D efforts in ozone sterilization.
• Early market presence in ozone food processing and commercial laundry systems since its founding in 1927.
• Established expertise in the licensing, manufacturing, and installation of complex ozone systems.
• However, the company's operational suspension since 2002 significantly diminishes the current relevance of these historical competitive advantages.

What Does CYPS Do?

Cyclo3pss Corporation, established in 1927 and headquartered in Salt Lake City, Utah, historically operated within the Healthcare sector, specifically focusing on Medical - Diagnostics & Research. The company's primary business activities encompassed the licensing, manufacturing, sale, and installation of specialized ozone food processing products. These systems were designed to enhance food safety and preservation through advanced ozone application technologies. Beyond the food industry, Cyclo3pss also developed and marketed ozone washing and laundry sorting and counting systems tailored for commercial and institutional laundries, addressing efficiency and sanitation needs in large-scale operations. In addition to its product lines, Cyclo3pss maintained a research and development arm dedicated to exploring and advancing technologies for the sterilization and disinfection of various consumer products. This R&D focus aimed to innovate solutions for public health and hygiene, aligning with its broader mission within the healthcare domain. For decades, the company contributed to specialized industrial and commercial sanitation markets with its unique ozone-based offerings. However, a pivotal moment occurred in July 2002 when the Board of Directors made the decision to immediately suspend all company operations. This drastic measure was necessitated by a critical inability to locate willing investors and secure the essential and suitable financing required to sustain its business activities. Consequently, Cyclo3pss Corporation has remained dormant since that time, with its historical operations ceased and no active business functions reported. Its legacy remains in its past contributions to ozone technology applications in food and laundry sectors, alongside its prior R&D endeavors.

What Products and Services Does CYPS Offer?

• Licenses, manufactures, sells, and installs ozone food processing products.
• Provides ozone washing and laundry sorting and counting systems for commercial and institutional laundries.
• Engages in research and development of technologies for sterilizing and disinfecting consumer products.
• Historically focused on advanced ozone application technologies for sanitation and preservation.
• Aimed to serve the food industry and large-scale commercial laundry operations.
• Conducted R&D to innovate solutions for public health and hygiene.
• Suspended all operations in July 2002 due to financial difficulties.

How Does CYPS Make Money?

• Historically generated revenue through the sale and installation of ozone-based processing and laundry systems.
• Engaged in licensing its proprietary ozone technology to other entities.
• Invested in research and development, aiming to commercialize new sterilization and disinfection technologies.
• Focused on B2B sales to commercial and institutional clients in food and laundry sectors.
• Operations have been suspended since July 2002, indicating no active revenue generation.

What Industry Does CYPS Operate In?

Cyclo3pss Corporation historically positioned itself within the specialized segments of the Healthcare sector, specifically under Medical - Diagnostics & Research, by focusing on ozone-based technologies. Its business model addressed critical needs in food safety and commercial sanitation. The market for ozone food processing, while niche, targets the broader food industry's demand for effective, chemical-free sterilization and preservation methods. Similarly, ozone washing and laundry systems cater to the commercial and institutional laundry sector, which continuously seeks efficient, environmentally friendly, and cost-effective solutions for high-volume sanitation. The company's R&D efforts in consumer product sterilization also aligned with public health trends. Historically, the competitive landscape would have included other providers of industrial sterilization equipment and commercial laundry solutions, as well as companies developing alternative disinfection technologies. However, with operations suspended since July 2002, Cyclo3pss is no longer an active participant in these markets, and its historical positioning is now a matter of record rather than current market influence.

Who Are CYPS's Key Customers?

• Commercial food processing facilities requiring sterilization and preservation solutions.
• Institutional laundries, such as hospitals, hotels, and large commercial cleaning services.
• Potentially, consumers indirectly through R&D for consumer product sterilization (if commercialized).
• Historically, businesses seeking advanced ozone technology for sanitation and efficiency.
• Currently, no active customer base due to suspended operations.

Company Profile

Cyclo3pss Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO William R. Stoddard. CYPS has traded publicly since 2010.

CYPS Financials

CYPS Latest News

No recent news available for CYPS.

CYPS Analyst Consensus

CYPS MoonshotScore

What Investors Ask About Cyclo3pss Corporation (CYPS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources